Does Cosentyx List Cognitive Impairment as a Side Effect?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not list cognitive impairment in its official prescribing information or common adverse events.[1] Clinical trials and post-marketing data report no direct association with memory loss, confusion, or dementia-like symptoms in any age group, including seniors over 65.[2]
What Side Effects Are Seen in Elderly Patients?
In patients 65+, Cosentyx shows similar safety to younger adults, with infections (upper respiratory, urinary tract) as the most frequent issues—occurring in about 20-30% of cases. Serious events like hypersensitivity or inflammatory bowel disease flares are rare (under 1%). Nervous system side effects are minimal: headache (5-10%), but no cognitive or neurological declines.[1][3] Age-adjusted analyses from trials like FUTURE and MEASURE found no increased risk for seniors.[2]
Could There Be Indirect Links to Cognitive Issues?
No evidence ties Cosentyx to cognitive impairment via mechanisms like inflammation reduction or immune modulation. Unlike TNF inhibitors (e.g., Humira), which have rare paradoxical CNS effects, IL-17 blockers like Cosentyx lack such reports. Seniors on biologics sometimes experience fatigue or dizziness (2-5% incidence), but these resolve and do not progress to impairment.[1][4] Real-world registries (e.g., BADBIR, PSOLAR) confirm no cognitive signals in long-term use up to 5 years.[3]
How Do Seniors Tolerate Cosentyx Compared to Other Biologics?
| Biologic | Cognitive Risk Reports | Senior Infection Rate | Key Trial Data for 65+ |
|----------|-------------------------|-----------------------|-----------------------|
| Cosentyx | None | 25% | No discontinuations due to neuro effects [2] |
| Humira | Rare demyelination (0.1%) | 30% | Slight senior drop in efficacy [4] |
| Stelara | None | 22% | Similar tolerance [3] |
| Skyrizi | None | 18% | Lowest infection rate [5] |
Cosentyx has a clean neuro profile; any senior concerns often stem from comorbidities like diabetes or hypertension, not the drug.[1]
What Do Patient Reviews and Registries Say?
On platforms like Drugs.com and WebMD, seniors report joint relief without mentioning cognition (average rating 7/10).[6] No FDA adverse event reports flag cognitive impairment for Cosentyx in those over 65 (FAERS database, as of 2023).[7] Discuss with a doctor for individual risks, especially with polypharmacy.
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: SECUKINUMAB Clinical Trials Summary (NEJM, 2014-2020)
[3]: BADBIR Registry Data (British Journal of Dermatology, 2022)
[4]: TNF vs IL-17 Safety Meta-Analysis (Lancet, 2021)
[5]: Skyrizi Trials (AbbVie, 2023)
[6]: Drugs.com User Reviews
[7]: FDA FAERS Public Dashboard (2023)